Sysmex Corporation, a global medical device manufacturing company with its HQ in Kobe, Japan, was looking to enlarge their US-based presence.
With San Diego as a target destination for expansion, Sysmex contacted EDC with details on the company’s plans to expand its life science operations by leveraging proprietary technologies to create new testing and diagnostic technologies that help provide optimal healthcare for all. Sysmex distributes and supports automated in vitro diagnostic hematology, coagulation and urinalysis analyzers, reagents and information systems for laboratories and healthcare facilities throughout the Western Hemisphere.
The company was interested in piloting their US presence with a research and development lab staffed with ten initial full-time employees. EDC provided a list of properties using a site selection database that met Sysmex’s requirements for location characteristics. In order to coordinate site logistic tours and provide Sysmex additional market perspectives on the potential locations, EDC leveraged its connections with CBRE’s research team. CBRE was able to conduct a tour with Sysmex on nine different locations across the region.
Sysmex is now in the process of finalizing their internal budget by mid-October, in order to establish their research and development site by December of this year. The Sysmex team is very positive regarding San Diego and establishing a future here.
The first cohort of biomanufacturing students at MiraCosta College is half way through their two-year bachelor’s degree program. That’s right – Oceanside-based MiraCosta Community College is one of only 15 community colleges in California to offer a bachelor’s degree program (114 total community colleges in CA). MiraCosta’s existing biotech associates degree program, which is the oldest in the county, helped the school gain prowess as a leading community college focused on life sciences. Building on that success, this new bachelor’s program will prepare students for work within San Diego’s lucrative biotechnology industry. The pioneer behind the program is Mike Fino: a UC San Diego Jacobs School alum, former industry researcher in regenerative medicine, and current Dean of Math & Sciences at MiraCosta.
With a background in industry, Mike Fino made the ideal moderator for EDC’s Link to San Diego: Life Sciences event at MiraCosta College in May. Formatted as a panel discussion followed by a networking session, Link to San Diego: Life Sciences welcomed representatives from Human Longevity Inc., Genentech, and BD to campus to speak about industry trends and lend advice to students on how they can prepare for a career in the San Diego industry. While open to all students, the program was primarily designed for MiraCosta’s biomanufacturing students to begin making industry connections and thinking about next steps as they work through their program.
The group of students who attended came prepared with resumes and thoughtful questions for the speakers. MiraCosta’s biomanufacturing BA program is a prime example of how San Diego’s community college system prepares its students based on the needs of our local economy, providing opportunities and value for residents and employers alike. Now, it’s our job to keep this bright and eager talent pool in San Diego.
From 2025 to 2050, the 65-and-older population is projected to almost double to 1.6 billion globally, whereas the total population will grow by just 34 percent over the same period. With this, it has become increasingly important to support our aging population, with health and wellness among top priority.
San Diego medical technology company and 2016 MetroConnect participant AVACEN Medical has developed technology to help ease some of the common ailments afflicting seniors. The AVACEN 100 is an FDA cleared, over-the-counter medical device that provides non-invasive, temporary arthritis and muscle pain relief, and muscle relaxation. Using microcirculation enhancement on the palms, the locally-made device helps warm and thin the blood, thereby dissipating heat throughout deep tissues and relieving joint pain associated by arthritis, muscle spasms, sprains and more.
Taking this San Diego-made technology global, the AVACEN 100 has just received the CE (Conformité Européenne) Mark approval to treat widespread pain associated with fibromyalgia. The CE Mark allows AVACEN to market its AVACEN 100 to the European Union’s 28 member countries where many prescription drugs, available in the U.S., have been rejected by regulatory officials for treating fibromyalgia pain.
Founded by Tom Muehlbauer in 2009, AVACEN’s revolutionary technology was originally developed to help alleviate his sister-in-law’s chronic pain. The company currently sells in two countries, with plans to expand into 10 more over the next year (thanks in part to the CE Mark). Sales have climbed to more than $1.5 million, with more than 20 percent of the sales coming from international markets.